Avanos Medical (NYSE:AVNS) Sets New 1-Year High - Here's What Happened

Key Points

• Avanos hit a new 52-week high — shares traded as high as $24.75 on Friday with about 132,581 shares changing hands, closing near $24.74.
• Quarterly results beat estimates — Avanos reported EPS of $0.29 vs. $0.24 expected and revenue of $180.9M vs. $174.7M, and set FY2026 guidance of $0.90–$1.10 (sell-side average ~1.07).
• Analysts remain cautious — mixed rating moves (Weiss and Zacks upgraded, Wall Street Zen downgraded) leave MarketBeat's average rating at "Reduce" with one Hold and one Sell.

Avanos Medical, Inc. (NYSE:AVNS - Get Free Report) shares reached a new 52-week high on Friday . The stock traded as high as $24.75 and last traded at $24.7350, with a volume of 132581 shares changing hands. The stock had previously closed at $24.71.

Analyst Ratings Changes

AVNS has been the subject of a number of research reports. Weiss Ratings raised shares of Avanos Medical from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday. Wall Street Zen cut shares of Avanos Medical from a "buy" rating to a "hold" rating in a report on Saturday, April 18th. Finally, Zacks Research raised shares of Avanos Medical from a "strong sell" rating to a "hold" rating in a report on Monday, January 26th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Reduce".

Avanos Medical Trading Down 0.1%

The stock's 50 day moving average price is $15.70 and its 200-day moving average price is $13.23. The company has a quick ratio of 1.26, a current ratio of 2.15 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $1.15 billion, a PE ratio of -15.63 and a beta of 1.05.

Avanos Medical (NYSE:AVNS - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.24 by $0.05. The firm had revenue of $180.90 million during the quarter, compared to analysts' expectations of $174.70 million. Avanos Medical had a negative net margin of 10.40% and a positive return on equity of 5.47%. The company's revenue for the quarter was up .7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.43 earnings per share. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. On average, sell-side analysts expect that Avanos Medical, Inc. will post 1.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Avanos Medical

Institutional investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC grew its stake in Avanos Medical by 132.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company's stock valued at $28,000 after acquiring an additional 1,423 shares in the last quarter. Versant Capital Management Inc grew its stake in Avanos Medical by 49.7% during the third quarter. Versant Capital Management Inc now owns 2,692 shares of the company's stock valued at $31,000 after acquiring an additional 894 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Avanos Medical by 969.3% during the second quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company's stock valued at $31,000 after acquiring an additional 2,307 shares in the last quarter. Wexford Capital LP purchased a new position in Avanos Medical during the third quarter valued at $70,000. Finally, Tower Research Capital LLC TRC grew its stake in Avanos Medical by 433.0% during the second quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company's stock valued at $77,000 after acquiring an additional 5,083 shares in the last quarter. 95.17% of the stock is owned by hedge funds and other institutional investors.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company's products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.